Sabbatini 2006.

Methods	Randomised open‐label multi‐centre phase I study
Participants	42 stage II‐IV ovarian cancer patients after chemotherapy for recurrence of disease with complete clinical response or measurable disease (< 2 cm)
Interventions	Intramuscular (IM) or subcutaneous (SC) monoclonal antibody (abagovomab ‐ CA‐125): 4 cohorts (2× IM; 2× SC; 0.2 mg or 2 mg)
Outcomes	Survival (time to progression) Tumour responses Immune response: humoral (Ab3, HAMA), cellular Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Standard 2 × 2 factorial design
Allocation concealment (selection bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of participants and personnel (performance bias) All outcomes	Low risk	No blinding or incomplete blinding, but review authors judge that the outcome is not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Reporting of attrition/exclusions insufficient to permit judgement of ‘low risk’ or ‘high risk’
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Low risk	No other sources of bias detected